Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL747203 | 0.90 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3ABL1BCR | |
| Trifluoroacetic Acid SCHEMBL747038 | 0.86 | CHRNA7 (0.42) | SLC6A4SLC6A2SLC6A3ABL1BCR | |
| SCHEMBL745851 | 0.75 | CHRNA7 (0.49) | SLC6A4SLC6A2SLC6A3CHRNA7PIK3CA | |
| Trifluoroacetic Acid SCHEMBL20958333 | 0.72 | SLC6A4 (0.73) | SLC6A4SLC6A2SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL20958365 | 0.72 | SLC6A4 (0.73) | SLC6A4SLC6A2SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL20958475 | 0.70 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL20958322 | 0.69 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL20958538 | 0.69 | SLC6A4 (0.73) | SLC6A4SLC6A2SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL20958428 | 0.69 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL1110457 | 0.69 | CHRNA7 (0.39) | SLC6A4SLC6A2SLC6A3CHRNA7PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431368-A1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | Abbott Laboratories (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2018380-B1 | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7872017-B2 | Fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, BMP2, ALKBH2 | SLC6A4 3130/4885SLC6A2 2602/4885SLC6A3 2587/4885 |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | MALT1, BMP2, ALKBH2 | SLC6A4 3130/4885SLC6A2 2602/4885SLC6A3 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.